Statistical analysis The statistical analyses were conducted in real time using the TriNetX platform
Ask about the evidence gap, alternative medications with lactation data, timing of therapy after weaning, and whether your maternal health urgency justifies selective use with monitoring
In published Phase 3 trials, mean weight loss for retatrutide at 80 weeks (28.3%) exceeded the mean for tirzepatide in SURMOUNT-1 at 72 weeks (22.5%)
Molecular durability is achieved through peptide engineering strategies that (i) confer resistance to DPP-4 cleavage, typically via N-terminal modification, and/or (ii) extend systemic exposure through fatty-acid acylation, which enhances albumin binding and slows renal clearance, thereby prolonging receptor activation [18]
Just in the last four months, I know 5 people (not GN patients) who are on them and none of those 5 have diabetes